Terns' oral weight-loss drug shows promise in early study, shares jump
Terns Pharmaceuticals said its oral obesity drug reduced weight by an average of 4.9% in an early-stage study, joining drugmakers vying for a share of the lucrative weight-loss treatment market and sending its shares up 27% on Monday.
Terns files $125m financing after positive obesity data
The financing announcement came right after Terns reported phase 1 results with its oral GLP-1 receptor agonist TERN-601, showing that a once-daily dose of the drug was able to achieve 5.5% weight loss in just 28 days, 4.9% more than a placebo, at the highest dose tested.
Terns Pharmaceuticals Inc (TERN) stock saw a decline, ending the day at $10.02 which represents a decrease of $-0.02 or -0.20% from the prior close of $10.04. The stock opened at $10.25 and touched a ...
Terns Pharmaceuticals shares rose 27% after early trials of their obesity drug showed significant weight loss.
Hosted on MSN20d
Terns Surges 29.6% in Three Months: Will the Momentum Continue?Shares of Terns Pharmaceuticals, Inc. TERN, a clinical-stage biopharmaceutical company, rose 29.6% in the past three months ...
The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...
Terns Pharmaceuticals shares dropped from Tuesday's 52-week high after the company priced an underwritten public offering of 11.9 million common shares at $10.50 a share. Shares in the clinical-stage ...
Terns intends to use the net proceeds from the proposed offering to fund research, clinical trials, development and manufacturing of the Company’s key product candidates, including TERN-701, TERN-601 ...
Structure Therapeutics (NASDAQ:GPCR), and Terns Pharmaceuticals (NASDAQ:TERN), which are all developing oral pills as weight loss treatments, are trading higher Friday following disappointing results ...
In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback